Biostock: Focus on CNS Diseases

Diseases of the central nervous system (CNS) and mental health issues represent a major burden on society, and there is considerable room for improvements of the current therapeutic alternatives. Swedish pharma company Gabather is working to alleviate this burden by developing therapies targeting the GABAA receptor, which is involved in a

Läs mer

Direkt: Rapportkommentar Gabather Q1 2020

00:20 The numbers 00:55 The key events of Q1 2020 02:05 The lockdown in Portugal 03:20 When will the study be finished? 04:05 How has the pandemic affected Gabathers day-to-day business 04:55 Viewer questions: Where do you see Gabather in 5 years 06:10 The difference between the EEG study and

Läs mer

Direkt: Rapportkommentarer Gabather Q4 2019

00:19 – Quick update on Q4 02:06 – GT002 study with patients03:25 – Ideal partner for Gabather Michael-Robin Witt, vd för Gabather som är ett bioteknikföretag som utvecklar nya läkemedel med fokus på behandling av sjukdomar i det centrala nervsystemet, intervjuas efter 4 KV delårsrapport.

Läs mer